StockNews.AI
OPTN
StockNews.AI
151 days

OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTN

1. OptiNose is proposed to be sold to Paratek Pharmaceuticals for $9.00 per share. 2. Investigation by KSF could impact the transaction's progress or terms significantly.

2m saved
Insight
Article

FAQ

Why Bullish?

The proposed acquisition offer of $9.00 per share reflects a premium valuation. Historical precedents show that acquisition proposals often lead to upward price movements.

How important is it?

The investigation could affect acquisition conditions, directly impacting investor confidence. Given the significant offer made, any changes could influence stock performance.

Why Short Term?

Investigation may create volatility in the short term. However, the acquisition’s structure and timing will influence long-term stability.

Related Companies

PRTK
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of OptiNose, Inc. (NasdaqGS: OPTN) to Paratek Pharmaceuticals. Under the terms of the proposed transaction, shareholders of OptiNose will receive $9.00 per share in cash, plus up to $5.00 per share in contingent value rights payable in the event that certain net revenue milestones are achieved by XHANC.

Related News